StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$84.78+10.38 (+13.95%)

Close on Nov 16, 2026Market cap $7.51BP/E –Yield –

CG Oncology profit margin

Profit margin (net margin) is net income as a percentage of revenue.

CG Oncology's profit margin for the twelve months ending Sep 30, 2026 was -3851.1%. For fiscal 2025 it was -3985.0%, against -7729.5% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-3985.0%+3744.5
FY2024Dec 31, 2024-7729.5%+16097.5
FY2023Dec 31, 2023-23827.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-3546.8%−917.3
Q2 FY2026Jun 30, 2026-6832.8%+59421.0
Q1 FY2026Mar 31, 2026-5558.8%+1414.4
Q4 FY2025Dec 31, 2025-1779.0%+45674.5
Q3 FY2025Sep 30, 2025-2629.5%+14399.3
Q1 FY2025Mar 31, 2025-66253.8%−63052.7
Q4 FY2024Dec 31, 2024-6973.2%+1648526.8
Q3 FY2024Sep 30, 2024-47453.5%+83302.1
Q2 FY2024Jun 30, 2024-17028.8%−12559.2
Q1 FY2024Mar 31, 2024-3201.1%–
Q4 FY2023Dec 31, 2023-1655500.0%–
Q3 FY2023Sep 30, 2023-130755.6%–
Q1 FY2023Mar 31, 2023-4469.6%–

More CG Oncology figures

See a number that looks wrong?